Targeting the androgen receptor in prostate and breast cancer: several new agents in development.

Triple-negative breast cancer: treatment challenges and solutions. Breast Cancer (Dove Med Press) (2016) 0.95

Androgen receptor expression predicts different clinical outcomes for breast cancer patients stratified by hormone receptor status. Oncotarget (2016) 0.86

Breast cancer molecular subtypes: from TNBC to QNBC. Am J Cancer Res (2016) 0.80

Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies. Oncotarget (2017) 0.78

Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer. Nat Rev Clin Oncol (2016) 0.78

Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11. Sci Rep (2017) 0.75

Family Matters: Collaboration and Conflict Among the Steroid Receptors Raises a Need for Group Therapy. Endocrinology (2016) 0.75

A Tale of Two Signals: AR and WNT in Development and Tumorigenesis of Prostate and Mammary Gland. Cancers (Basel) (2017) 0.75

Fourth-Generation Progestins Inhibit 3β-Hydroxysteroid Dehydrogenase Type 2 and Modulate the Biosynthesis of Endogenous Steroids. PLoS One (2016) 0.75

Expression Analysis of Long Non-Coding PCAT-1in Breast Cancer. Int J Hematol Oncol Stem Cell Res (2017) 0.75

Androgen receptor expression and breast cancer mortality in a population-based prospective cohort. Breast Cancer Res Treat (2017) 0.75

Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58

Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79

Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54

Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest (2011) 14.22

Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med (2014) 12.29

Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res (2008) 10.66

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87

Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst (2002) 9.65

Androgen receptor in prostate cancer. Endocr Rev (2004) 7.92

Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 7.32

HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol (2010) 7.16

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med (1989) 7.01

Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol (2004) 6.95

In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet (1995) 6.60

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2012) 6.49

Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res (2007) 5.97

Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res (2008) 5.79

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A (2010) 5.59

Identification of molecular apocrine breast tumours by microarray analysis. Oncogene (2005) 5.27

Molecular biology of the androgen receptor. J Clin Oncol (2002) 5.08

Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res (2005) 5.04

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet (2000) 5.03

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res (2009) 4.68

Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J Clin Oncol (2015) 4.44

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2015) 4.40

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol (2004) 4.25

Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell (2010) 4.16

Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists' Collaborative Group. Lancet (1995) 3.75

Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife (2013) 3.49

An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene (2006) 3.48

Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol (2014) 3.44

Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res (1999) 3.41

Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med (2000) 3.26

Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer (2002) 3.05

ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res (2012) 2.51

Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol (2003) 2.32

Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res (2013) 2.30

Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell (2011) 2.23

Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology (2000) 2.16

Endogenous steroid hormone concentrations and risk of breast cancer: does the association vary by a woman's predicted breast cancer risk? J Clin Oncol (2006) 2.14

Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat (2010) 2.14

TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol (2011) 2.14

Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res (2011) 2.11

Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res (2009) 2.10

Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res (2013) 2.09

The Use of Testosterone Propionate in the Treatment of Advanced Carcinoma of the Breast. Ann Surg (1946) 2.09

Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res (2003) 2.07

Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol (2003) 2.07

Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res (2009) 1.98

Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol (2009) 1.94

Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol (1997) 1.90

Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol (1993) 1.86

Expression of androgen receptors in primary breast cancer. Ann Oncol (2009) 1.85

Androgen receptor: an overview. Crit Rev Eukaryot Gene Expr (1995) 1.81

Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst (1996) 1.77

Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer (2012) 1.75

Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology (1994) 1.75

Androgen receptor mutations in prostate cancer. Cancer Res (2000) 1.74

Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol (2014) 1.74

Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol (1993) 1.73

Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer (2008) 1.73

Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res (2009) 1.68

An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest (2013) 1.64

Interactions between androgen and estrogen receptors and the effects on their transactivational properties. Mol Cell Endocrinol (2000) 1.62

Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol (1995) 1.58

Androgen receptor gene amplification and protein expression in recurrent prostate cancer. J Urol (2003) 1.58

Taxonomy of breast cancer based on normal cell phenotype predicts outcome. J Clin Invest (2014) 1.58

Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res (2009) 1.54

Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol (1993) 1.47

Diverse roles of androgen receptor (AR) domains in AR-mediated signaling. Nucl Recept Signal (2008) 1.47

Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol (2011) 1.40

Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treat Rev (2012) 1.40

Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol (2008) 1.36

Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat (2009) 1.35

Recent advances in androgen receptor action. Cell Mol Life Sci (2003) 1.34

Role of the androgen receptor in human breast cancer. J Mammary Gland Biol Neoplasia (1998) 1.33

Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod Pathol (2011) 1.33

Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat (2011) 1.32

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res (2014) 1.23

Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol (2013) 1.21

The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer. Med Oncol (2011) 1.13

Androgen receptors in breast cancer. Cancer (1984) 1.13

Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo. Mol Cancer Ther (2013) 1.12

Sex hormone-induced mammary carcinogenesis in female noble rats: the role of androgens. Carcinogenesis (1999) 1.10

Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res (2014) 1.09

Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med (1989) 1.09

Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers. Virchows Arch (2010) 1.08

Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer. Mol Cancer Ther (2014) 1.08

Androgens and the breast. Breast Cancer Res (2009) 1.06

Androgen receptor expression predicts breast cancer survival: the role of genetic and epigenetic events. BMC Cancer (2012) 1.05

Androgen receptor as a targeted therapy for breast cancer. Am J Cancer Res (2012) 1.04

Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. Ann Surg Oncol (2014) 1.04

Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified? Am J Cancer Res (2014) 1.03

Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. Int J Oncol (2012) 1.02

Complexities of androgen receptor signalling in breast cancer. Endocr Relat Cancer (2014) 0.97